Zobrazeno 1 - 10
of 117
pro vyhledávání: '"JL Marenco"'
Autor:
M Andres, JL Marenco, L Silva, J Narvaez, M Freire, M Gantes, G Bonilla, C Montilla, A Olive, E Tomero, E Raya, I Castellvi, A Fernández-Nebro, E Uriarte, J Calvo-Alén, C Erausquin, S Muñoz, C Mouriño, A Boteanu, R Melero, JM Pego-Reigosa, V Torrente-Segarra, A Lois-Iglesias, R Iñigo, M Galindo Izquierdo, V Balboa-Barreiro, C Fito, A Morasat, G Santos-Soler, E León, V Taboada, O Ibarguengoitia, M Fernandez-Castro, JA Hernadez-Beirian, B Hernández-Cruz, J Pérez-Venegas, A Pecondon, N Lozano, AP Cacheda, JJ Alegre, J Calvet, T Vázquez, Q Víctor, T Otón, J Martínez Barrio
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/b6168e3f2cd54178b9347ef9b8048e89
Autor:
A Lois-Iglesias, R Iñigo, M Galindo Izquierdo, J Calvo-Alén, V Balboa-Barreiro, C Mouriño, A Olivé, R Melero, A Fernández-Nebro, M Andrés, C Erausquin, E Tomero, C Fito, E Uriarte, M Freire, C Montilla, A Morasat, G Santos-Soler, A Boteanu, E León, J Narvaez, V Taboada, L Silva, O Ibarguengoitia, M Fernandez-Castro, JA Hernadez-Beirian, M Gantes, B Hernández-Cruz, J Pérez-Venegas, A Pecondon, N Lozano, AP Cacheda, G Bonilla, V Torrente-Segarra, I Castellvi, JJ Alegre, J Calvet, JL Marenco, E Raya, T Vázquez, Q Víctor, S Muñoz, T Otón, J Martínez Barrio, JM Pego-Reigosa
Publikováno v:
Friday 07 October 2022 from 13:00 to 14:10.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a588ec3e7e312d0013011b7f9763bf38
https://doi.org/10.1136/lupus-2022-elm2022.175
https://doi.org/10.1136/lupus-2022-elm2022.175
Autor:
A. M. Patiño-Trives, Dolores Ruiz-Montesinos, Mª Dolores Toledo-Coello, M. D. C. Abalos-Aguilera, JL Marenco, Carlos Rodríguez-Escalera, C.M. Romero-Barco, F. U. Pilar, María Luque-Tévar, M. Romero-Gómez, Juan Antonio Marin-Sanz, J. J. Pérez Venegas, D. Ruiz, C. Dominguez, María Ángeles Aguirre-Zamorano, A. Escudero Contreras, Julia Uceda, N. Barbarroja Puerto, R. Ortega Castro, I. Arias de la Rosa, C. Perez-Sanchez, C. Lopez-Pedrera, Natalia Mena-Vázquez, Antonio Fernández-Nebro, E. Collantes Estevez, Clementina López-Medina
Publikováno v:
Annals of the Rheumatic Diseases. 80:469-470
Background:TNF inhibitors (TNFi) represent an extraordinary advance in the management of Rheumatoid Arthritis (RA). Despite their benefits, there is a percentage of patients (20–40%) that do not achieve clinical improvement. Therefore, it is necess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::185762e853ef68192f9403c815e7d21e
https://doi.org/10.1136/annrheumdis-2021-eular.2549
https://doi.org/10.1136/annrheumdis-2021-eular.2549
Publikováno v:
Abstracts.
Career situation of first and presenting author Student for a master or a PhD. Introduction Recently new therapeutic targets have been approved for the treatment of psoriatic arthritis (PSA). We have limited experience in real clinical practice. Obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e27d58ba2cd91e953d82dd52eada3c2
https://doi.org/10.1136/annrheumdis-2018-ewrr2019.83
https://doi.org/10.1136/annrheumdis-2018-ewrr2019.83
Publikováno v:
Abstracts.
Career situation of first and presenting author Assistant. Introduction The Raynaud phenomenon (RP) affects 3%–5% of the population. Most RPs are primary. The risk of the onset of autoimmune disease associated with RP (ADRP) is arround 12%, and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75e6e7abbb8945597a46f14897a84a07
https://doi.org/10.1136/annrheumdis-2018-ewrr2019.40
https://doi.org/10.1136/annrheumdis-2018-ewrr2019.40
Publikováno v:
Abstracts.
Career situation of first and presenting author Assistant. Introduction Psoriatic arthritis (PsA) belongs to the family of spondyloarthritis, with an incidence of 6 cases per 1 00 000 inhabitants. Ustekinumab is an inhibitor of IL 12/13 approved for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84c2f767215fccb2c1444057759b2784
https://doi.org/10.1136/annrheumdis-2018-ewrr2019.130
https://doi.org/10.1136/annrheumdis-2018-ewrr2019.130
Autor:
C. Lopez-Pedrera, M. D. C. Abalos-Aguilera, A. M. Patiño-Trives, I. Arias de la Rosa, M. D. Ruiz Montesinos, A. Escudero Contreras, Carlos Perez-Sanchez, Julia Uceda, N. Barbarroja Puerto, M. Romero-Gómez, María Luque-Tévar, Maria Angeles Aguirre, R. Ortega Castro, D. Ruiz, F. U. Pilar, Natalia Mena-Vázquez, Antonio Fernández-Nebro, Carlos Rodríguez-Escalera, J. J. Pérez Venegas, Eduardo Collantes-Estevez, C. Dominguez, C.M. Romero Barco, JL Marenco, Mª Dolores Toledo-Coello
Publikováno v:
Annals of the Rheumatic Diseases. 79:951.2-952
Objectives:To evaluate the changes promoted in levels of circulating inflammatory mediators in RA patients in response to TNF-α inhibitors (TNFi) and anti-CD20 therapies, in order to identify biomarkers of clinical efficacy and potential predictors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b49fef87c03f46fd41f18beed911c06
https://doi.org/10.1136/annrheumdis-2020-eular.4442
https://doi.org/10.1136/annrheumdis-2020-eular.4442
Publikováno v:
Annals of the Rheumatic Diseases. 79:1493.2-1493
Background:Lupus nephritis (LN) is a potentially life-threatening complication of systemic lupus erythematosus (SLE). Standard treatment of this entity includes glucocorticoids (GC) and immunosuppressants such as cyclophosphamide (CF), with remission
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b836478f02aac5b5ab06ebfd7a076709
https://doi.org/10.1136/annrheumdis-2020-eular.4305
https://doi.org/10.1136/annrheumdis-2020-eular.4305
Publikováno v:
Diagnostics and imaging procedures.
Background The Raynaud phenomenon (RP) is very common throughout the world, especially in cold climates, affecting approximately 3%–5% of the population. Most RPs are primary. The risk of the onset of autoimmune disease associated with RP (ADRP) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1e4d64054c9ebf75e58852a2bdd750f
https://doi.org/10.1136/annrheumdis-2018-eular.5759
https://doi.org/10.1136/annrheumdis-2018-eular.5759
Autor:
Elvira Díez-Álvarez, C. A. Montilla-Morales, J.M. Nolla, P. García de la Peña, E. Uriarte Isacelaya, Javier Ibáñez, A. Juan Mas, Mariano Andrés, Jaime Calvo-Alén, Juan José Alegre, Gregorio Santos-Soler, J. Narváez, M.L. Horcada, A. Olivé, Alina Boteanu, Tomas R. Vazquez-Rodriguez, I. Castelvi, Francisco Javier Toyos, Iñigo Rúa-Figueroa, Mercedes Freire, Tatiana Cobo-Ibáñez, Ángela Pecondón-Español, H. Borrell, JL Marenco, Fernando Sánchez-Alonso, José Luis Andreu, Rosario García-Vicuña, Nuria Lozano-Rivas, Roman Blanco, E. Ruiz Lucea, J. Hernández Beiraín, Antonio Fernández-Nebro, José M. Pego-Reigosa, Mireia Moreno, Francisco Javier López-Longo, Gemma Bonilla, Ana Sánchez-Atrio, María Galindo, Marian Gantes
Publikováno v:
FRIDAY, 15 JUNE 2018.
Objectives To investigate the primary respiratory manifestations (PRM) in SLE. Methods All patients in the RELESSER cohort were retrospectively investigated for the presence of PRM Results At least one PRM was present in 11.3% (365/3215) of cases. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1be544d63750e0f20bd6d2108e4bbd6f
https://doi.org/10.1136/annrheumdis-2018-eular.6436
https://doi.org/10.1136/annrheumdis-2018-eular.6436